333 related articles for article (PubMed ID: 26275071)
1. Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
McGann PT; Tshilolo L; Santos B; Tomlinson GA; Stuber S; Latham T; Aygun B; Obaro SK; Olupot-Olupot P; Williams TN; Odame I; Ware RE;
Pediatr Blood Cancer; 2016 Jan; 63(1):98-104. PubMed ID: 26275071
[TBL] [Abstract][Full Text] [Related]
2. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
McGann PT; Williams TN; Olupot-Olupot P; Tomlinson GA; Lane A; Luís Reis da Fonseca J; Kitenge R; Mochamah G; Wabwire H; Stuber S; Howard TA; McElhinney K; Aygun B; Latham T; Santos B; Tshilolo L; Ware RE;
Am J Hematol; 2018 Aug; 93(4):537-545. PubMed ID: 29318647
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
4. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
Power-Hays A; Tomlinson GA; Tshilolo L; Santos B; Williams TN; Olupot-Olupot P; Smart LR; Aygun B; Lane A; Stuber SE; Latham T; Ware RE
Am J Hematol; 2024 Apr; 99(4):625-632. PubMed ID: 38332651
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.
Olupot-Olupot P; Tomlinson G; Williams TN; Tshilolo L; Santos B; Smart LR; McElhinney K; Howard TA; Aygun B; Stuber SE; Lane A; Latham TS; Ware RE
Blood; 2023 Mar; 141(12):1402-1410. PubMed ID: 36375125
[TBL] [Abstract][Full Text] [Related]
7. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.
Dexter D; McGann PT
Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
[TBL] [Abstract][Full Text] [Related]
10. Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola.
Chambers TM; Kahan S; Camanda JF; Scheurer M; Airewele GE
Pediatr Blood Cancer; 2018 Dec; 65(12):e27365. PubMed ID: 30051651
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
12. Effective use of hydroxyurea for sickle cell anemia in low-resource countries.
Power-Hays A; Ware RE
Curr Opin Hematol; 2020 May; 27(3):172-180. PubMed ID: 32205588
[TBL] [Abstract][Full Text] [Related]
13. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662
[TBL] [Abstract][Full Text] [Related]
14. Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.
Smart LR; Ambrose EE; Balyorugulu G; Songoro P; Shabani I; Komba P; Charles M; Howard TA; McElhinney KE; O'Hara SM; Odame J; Nakafeero M; Adams J; Stuber SE; Lane A; Latham TS; Makubi AN; Ware RE
Acta Haematol; 2023; 146(2):95-105. PubMed ID: 35977532
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens.
Teigen D; Opoka RO; Kasirye P; Nabaggala C; Hume HA; Blomberg B; John CC; Ware RE; Robberstad B
Pharmacoeconomics; 2023 Dec; 41(12):1603-1615. PubMed ID: 37462838
[TBL] [Abstract][Full Text] [Related]
16. Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa.
Galadanci NA; Kanter J
Lancet Haematol; 2024 Jun; 11(6):e393-e395. PubMed ID: 38701813
[No Abstract] [Full Text] [Related]
17. Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial.
Anyanwu JN; Williams O; Sautter CL; Kasirye P; Hume H; Opoka RO; Latham T; Ndugwa C; Ware RE; John CC
JMIR Res Protoc; 2016 Jun; 5(2):e110. PubMed ID: 27339303
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and treatment of relative anemia in children with sickle cell disease in sub-Saharan Africa.
Bello-Manga H; DeBaun MR; Kassim AA
Expert Rev Hematol; 2016 Nov; 9(11):1031-1042. PubMed ID: 27677923
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi.
Mvalo T; Topazian HM; Kamthunzi P; Chen JS; Kambalame I; Mafunga P; Mumba N; Chiume M; Paseli K; Tegha G; Kumwenda W; Heimlich JB; Ellis G; Key N; Gopal S; Hoffman I; Ataga KI; Westmoreland KD
Pediatr Blood Cancer; 2019 Nov; 66(11):e27954. PubMed ID: 31397075
[TBL] [Abstract][Full Text] [Related]
20. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia.
Jeste ND; Sánchez LM; Urcuyo GS; Bergés ME; Luden JP; Stuber SE; Latham TS; Mena R; Nieves RM; Ware RE
JMIR Res Protoc; 2017 Jun; 6(6):e107. PubMed ID: 28576754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]